Next-Gen MPN Care: Highlighting Research from Memorial Sloan Kettering with Dr. Raajit Rampal image

Next-Gen MPN Care: Highlighting Research from Memorial Sloan Kettering with Dr. Raajit Rampal

Jun 22, 2026
03:30PM - 04:30PM EDT
Online Event
Overview

Join the HealthTree Foundation for an exclusive look into the cutting-edge MPN research happening at Memorial Sloan Kettering with renowned expert Dr. Raajit Rampal. This session will explore the latest advancements in targeted therapies and genomic discoveries that are shaping the future of personalized care for myeloproliferative neoplasms. Gain valuable insights into how these next-generation treatments are moving from the lab to the clinic to improve outcomes and quality of life for the MPN community.

 

Agenda
3:30 PM
Introductions
Dalton Bean

Dalton introduces the agenda of the event and featured speaker Raajit Rampal, MD

3:35 PM
Presentation
Raajit Ramal, MD, PhD

Join the HealthTree Foundation for an exclusive look into the cutting-edge MPN research happening at Memorial Sloan Kettering with renowned expert Raajit Rampal.

4:05 PM
Questions & Answers
Audience

Bring your questions!

Speakers & Moderators
Healthtree contact Dalton Bean

Dalton Bean

Dalton joined HealthTree in 2024 as the MPNs and MDS Program Manager. He is passionate about helping patients gain a better understanding of their health and treatment and sees it as a way to help empower individuals and their families who are affected by these diseases. Prior to joining HealthTree Dalton earned a Master’s Degree in Oncological Sciences while studying various different blood cancers. When not interacting with patients he is an avid snowboarder and hiker.
Healthtree contact Raajit Ramal, MD, PhD

Raajit Ramal, MD, PhD

Raajit Rampal, MD, PhD, is a Hematological Oncologist at the Memorial Sloan Kettering Cancer Canter, New York, KY, specializing in myeloproliferative neoplasms (MPNs) and leukemia. Dr. Rampal is a dedicated and active researcher focusing on developing new and innovative approaches to treating MPNs and leukemia. He also works to develop and run novel clinical trials with molecularly targeted agents for patients with MPNS and leukemia.